Neurelis, Inc., is a leading neuroscience company focused on the development and commercialization of therapeutics for the treatment of epilepsy and other neurologic disorders. Our unique drug portfolios strive to address unmet needs in patient care.
Location: United States, California, San Diego
Employees: 51-200
Total raised: $264M
Founded date: 2007
Investors 2
| Date | Name | Website |
| - | OrbiMed | orbimed.co... |
| - | HBM Partne... | hbmpartner... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 11.08.2021 | - | $150M | OrbiMed |
| 11.03.2021 | Series D | $114M | - |
Mentions in press and media 19
| Date | Title | Description |
| 02.02.2026 | Sixth Annual Seizure Action Plan Awareness Week to Promote Seizure Preparedness Nationwide, Feb. 9-16, 2026 | The Seizure Action Plan Coalition, a collaboration managed by Epilepsy Alliance America, will host the Sixth Annual Seizure Action Plan (SAP) Awareness Week from February 9–16, 2026. The national epilepsy awareness campaign focuses on seizu... |
| 27.10.2025 | Couples Impacted by Epilepsy Come Together for Groundbreaking Relationship Retreat in Princeton, NJ | Couples impacted by epilepsy gathered at The Peacock Inn in Princeton, NJ, for Navigating Us: Connecting Through the Epilepsy Journey, a relationship-centered retreat hosted by Epilepsy Services of New Jersey. The two-day event offered guid... |
| 18.10.2023 | Aculys Pharma delivers positive Phase 3 clinical study interim analysis result of a diazepam nasal spray: an antiepileptic drug for the treatment of epileptic seizures | These results are from Japan's first domestic Phase 3 clinical trial of an intranasally administered antiepileptic drug for Japanese patients aged 6 to 17 for the treatment of status epilepticus or epileptic seizures that may lead to status... |
| 23.01.2023 | Startups measuring the brain that you need to know | Companies are using biomarkers to diagnose and treat mental illness and other neurological disorders Mental illness is considered the silent pandemic that's been overlooked since the start of COVID. The World Health Organization found the g... |
| 26.01.2022 | Aculys Pharma signed an exclusive licensing agreement with Neurelis, Inc. for the development and commercialization of VALTOCO® | Aculys Pharma, Inc. (“Aculys Pharma” Headquarters: Fujisawa City, Kanagawa Prefecture, Representative Director and CEO: Kazunari Tsunaba), a new biopharmaceutical company focused on the development and commercialization of new innovative dr... |
| 11.08.2021 | Neurelis Receives $150M Senior Term Loan Facility From OrbiMed | - |
| 11.08.2021 | Neurelis Secures Senior Term Loan Facility Of Up To $150 Million From Orbimed | - |
| 11.08.2021 | Neurelis Secures Senior Term Loan Facility Of Up To $150 Million From OrbiMed | |
| 19.04.2021 | Neurelis Announces Five Poster Presentations for the Annual Meeting of the American Academy Of Neurology | |
| 12.04.2021 | Neurelis Announces Two Poster Presentations for the Annual Meeting of the Academy of Managed Care Pharmacy |
Show more